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Over the past centuries life expectancy of women has increased significantly, however, the 
onset  of menopause has not changed ( in Hungary at around 50-52 years of age). One third of 
women’s life is lived without ovarian estrogen exposure. The frequency of pathologies, 
characteristic  for menopause is increased. In the gynecologic practice postmenopausal 
bleeding is of significance. According to literature data endometrial atrophy is considered to 
be the main cause of postmenopausal bleeding. Organic pathologies, such as endometrial 
polyps, uterine fibroids, and occasionally endometrial hyperplasia may also contribute to 
abnormal postmenopausal uterine bleeding. In about of 10 per cent of cases the underlying 
endometrial cancer may present with abnormal uterine bleeding.  
Follow-up of patients, treated with menopausal hormone therapy is also an important 
gynecologic issue over the perimenopausal ages. 
For  good compliance endometrial safety (amenorrhoea during treatment)  is utmost during 
postmenopausal hormonal therapy . Unopposed estrogen exposure to the endometrium  results 
in endometrial hyperplasia and carcinoma. For this reason continuous combined treatment 
(fixed daily dose of estrogen plus progestogen supplemetation) is indicated for non-
hysterectomized women.  In addition to the classical schemes of HRT over the past decade 
new drugs were implemented into postmenopausal hormonal clinical practice, including 
tibolone and SERMs. In response to  postmenopausal HRT endometrial atrophy develops. 
Despite this effect in a significant proportion of patients abnormal uterine bleeding occurs and 
patients cease HRT. Exact causes of abnormal uterine bleeding during continuous combined 






The objective of my thesis was to investigate the interaction between sonographic endometrial 
morphologic changes and cellular hormonal mechanisms and the impact of postmenopausal 
HRT on these. The following aims were addressed: 
 
1. Is there any difference between healthy postmenopausal women and patients with 
postmenopausal uterine bleeding in circulating serum hormone levels (FSH, E2, 
progesterone)? 
2. Is there any correlation between endometrial thickness measured by transvaginal 
ultrasound (TV-US) and histopathologic findings in patients treated for 
postmenopausal  beeding ? 
3. Is 3D ultrasound measurement of endometrial volume feasible for early detection of 
endometrial pathologies ? 
4. What are the molecular mechanisms of  endogenous estrogen action within human 
endometrium during postmenopause ? 
5. What is the action of  non-genomic ERalpha/PI3K/Akt signaling pathway in healthy 
and pathologic human endometrium and in response to continuous combined HRT and 
tibolone therapy ? 
6. Finally, to test, whether investigation of genomic and non-genomic effects of 
estrogens in the postmenopausal endometrium may predict a future abnormal uterine 






Patients and methods 
 
Patients 
At the  Department of Obstetrics  and  Gynecology of the University Medical School of Pécs 
between March, 2005 and January 2007 one-hundred and twenty four postmenopausal women 
were enrolled in the study. 
Group I. consisted of 50 patients with postmenopausal uterine bleeding. 
Group II. consisted of 38 postmenopausal women  without uterine bleeding to serve as 
controls. 
Group III. was the postmenopausal HRT group of 36 patients, of whom 27 patients were 
treated with continuous combined treatment (1 or 2 mg of crystallized 17beta-estradiol/1mg 
norethisteron-acetate) and 9 patients with tibolone in a dose of 2.5 mg/day, respectively. 
 
 
Serum hormone measurement 
FSH, estradiol (E2) and progesterone levels in serum of patients were determined by radio-
immunoassay (Byk-Sangtec Diagnostica, Dietzenbach, Germany). 
 
 
TV 2D US examination 
TV US was performed prior to histologic endometrial sampling by Kretz Voluson 730 real-
time ultrasound scanner (Kretz Technik AG., Zipf, Austria) in lithotomy position of patients 
with an emptied urinary bladder. Endometrial thickness was measured with a 5-8 MHz 




The 3D volume measurement of the endometrium was done using VOCAL software of the 
3D ultrasound scanner after visualizing the endometrium in midsagittal view with a 5-8 MHz 
endovaginal volume transducer (90° field of view). The 3D mode was activated and the 
mobile sector was set to cover the region of interest (ROI), the volume sector angle was set as 
60° and the fast volume acquisition was used to avoid motion-artifacts. After volume 
acquisition 3D volumes were immediately stored in RAM memory of the equipment. Volume 
measurements were done off-line from reloaded volumes with the simultaneous analysis of 
the three ortogonal planes. With the VOCAL software the A-plane was selected to be the 
reference image, the two poles were determined with the caliper  to fix the axis of rotation, 
then the manual contour mode was engaged,  and 6 rotational steps (per 30°) were selected to 
draw the contour lines of the rotated planes. After editing the 6 contours the virtual 3D image 







Endometrial samples were retrieved by the following methods, approved by the Institutional 
Review Board on Human Research of the University of Pécs: 
1. In patients with abnormal uterine bleeding endometrial samples were collected during 
diagnostic curettage or hysterectomy (if endometrial cancer was ruled out by histology 
within 6 months). 
2. Patients with benign gynecologic leasions (uterine prolapse, fibroid, ovarian cysts) 
undergone hysterectomy served as controls together with healthy patients, seen at our 
menopausal outpatient clinic as potential candidates for HRT. Endometrial samples 
were retrieved after written informed consent had been obtained following routine 
gynecologic cervical cancer screening. 
3. Endometrium biopsy was done at yearly check-up of patients receiving menopausal 
hormone therapy.  
 
Endometrium biopsy was accomplished using  „Suresample” Wallace Endometrium Sampler 
Set. Histopatholgic examinations were perfomed et Department of Pathology of the 
University Medical School of Pécs. 
 
 
The receptor studies 
The individual tissue samples were homogenized at 4°C in 1ml/100 mg tissue of ice cold 
Buffer I (50 mM Tris-Cl pH 8.0, 1mM Na-orthovanadate) for 30-40 sec, then we added 
1ml/100 mg tissue of ice cold Buffer II (10mM Tris-Cl pH 8.0, 1mM EDTA, 1%SDS, 5% 
mercaptoethanol, 40% glycerol) was added and the samples were homogenized further bathed 
in boiling water for 5 min and centrifuged. Supernatants were stored at -20˚C. After 
electrophoresis and blotting the membranes with the transferred proteins were treated with 
primary antibodies. As secondary antibody we used anti-rabbit antibody conjugated with IgG 
conjugated HRP. Blots were developed and visualized by chemiluminescence (ECL). Western 
blot analyses were conducted at least three times in three independent preparations of tissues 




The data are presented as mean ±  S.D.   Group differences were analyzed by ANOVA 
followed by Student-Newman-Keul’s multiple range tests. Pearson’s correlation test was used 
to analyze the relationship between the obtained changes. Differences were considered to be 







1. Clinical data 
We found significant difference between group I. (postmenopausal uterine bleeding) and 
group II. (control postmenopausal women) in mean age, time and length of menopause, body 
weight, and in body mass index. 
There was no significant difference between  group II. (controls) and group III. (HRT-







Clinical characteristics of patients 
 




Group III.  
n=36 
Mean age (years) 63.8±7.6 56.3±5.5 56.6±5.8 
Bodyweight (kg) 84.8±12.6 72.6±9.8 70.9±8.8 
Body Mass Index  (kg/m2) 31.3±4.3 25.1±5.2 27.0±4.8 
Number of gravidities (n) 4.2±1.8 4.1±2.1 3.3±1.9 
Number of deliveries (n) 2.1±1.9 2.1±1.8 1.9±1.8 
Menarche (years) 14.6±1.8 14.8±1.9 14.6±1.9 
Onset of menopause (years) 53.1±3.1 50.2±2.5 49.7±3.9 
Length of  menopause  (years) 13.3±6.8 4.8±3.7 4.9±4.9 
Duration of HRT (years) - - 4.2±2.1 
 
2. Results of serum hormone levels 
In group I. FSH levels were significantly lower and estradiol levels were higher, respectively, 
compared to that of group II. Progesterone levels were higher in group I., but the difference 




Levels of serum hormones 
 






FSH (U/l) 58.40±25.38 78.17±44.50 58.9±39.91 
Estradiol (pmol/l) 69.52±51.61 40.47±49.37 128.02±136.24 

















3. Comparison of sonographic  and histologic endometrial findings 
Uterine size and mean endometrial thickness were significantly greater in group I. compared 
















Mean uterine size (cm) 7.66±3.4 6.81±2.1 6.75±2.0 
Mean (range) endometrial thickness 
(mm) 




   
Normal endometrium   (n)    
       Proliferative endometrium 4 2  
       Blood discrasia in endometrium 5   
       Inactive secretory endometrium  3 3 
       Irregular secretory phase 2 4 10 
       Regressive endometrium  8 8 
       Endometrial atrophy 3 9 15 
       Cystic endometrial atrophy 4 8  
    
Endometrial polyp 5 2  
    
Endometrial hyperplasia    
          Simplex 9 2  
          Glandular-cystic 3   
          Atypic  2   
Endometrial carcinoma 13   































≤4mm 72 1   
4,1-8mm 10 13   
8,1-12mm  9 2 1 
12,1-16mm  2  1 
16,1-20mm    5 
≥20mm    6 
∑ 82 25 2 13 
 
4. With respects to endometrial hyperplasia and carcinoma  significant correlation was found 






The serum hormone levels and endometrial pathology 
 












FSH 67.22±37.36 66.13±8.95 67.75±44.03 59.79±28.97 
Estradiol 57.03±54.05 52.81±4.14 97.87±74.02 62.71±56.13 
Progesterone 0.76±0.72 0.96±0.75 0.85±0.35 0.83±0.88 
 
 
5. Results of three-dimensional ultrasound volumetry 
In group I. significantly larger endometrial volumes were measured by 3D-sonography 
compared to that of group II. and III. There was no significant difference in endometrial 
volume between groups II. and III. In group III. endometrial volume was slightly greater 
among patients treated with continuous combined  hormone treatment compared with 
tibolone-treated patients. 











Endometrial volume in the study groups 
 




















CCT: Continuous combined hormone treatment 
 
 
Mean endometrial volume was significantly greater in patients with endometrial pathologies 
compared to those, who had a negative histologic finding. Based on our results the cut-off 
value of volume for endometrial carcinoma was found to be 12.1 ccm, below this volume no 
endometrial malignancy was detected. 












Mean ( range) endometrial volumen 
(ccm) 
Normal endometrium   (n=82) 1.9(0.9-2.4) 
  
Endometrial polyp    (n=7) 6.8(7.8-9.6) 
  
Endometrial hyperplasia (n=20) 8.5(5.8-14.1) 
  
Endometrial carcinoma (n=13) 19.4(12.1-66.2) 
 
 
6. Results of the receptor studies 
The expression of pAkt was significantly higher in the proliferative phase of the menstrual 
cycle compared to that of the secretory phase and postmenopause. Similar significancy was 
not detected with respect to pER. Our results suggested, that there was significant correlation 
between changes of pAkt and serum estradiol levels. We found parallel changes between the 
expression of pAkt and pERalpha. 
The expression of pAkt and pERalpha was significantly higher in group III. (HRT patients) 
compared with group II. (controls). There was no difference in ERalpha levels between HRT-
treated and control patients. 
With the analysis of endometrial histologic findings and expression of pERalpha and pAkt we 
found, that in proliferative endometrial changes the activation was abundant compared to that 
of contol patients with atrophic endometrium, however, there was no statistically significant 







1. In patients with postmenopausal uterine bleeding serum estradiol levels are 
significantly higher compared to that of healthy postmenopausal women. This 
finding substanciates the fact, that changes of endogenous estrogen levels (that 
might be influenced by many factors) have significant impact on proliferative 
changes of the postmenopausal endometrium. Continuous unopposed estrogen 
exposure to the endometrium results in endometrial hyperplasia, moreover, 
endometrial carcinoma may develop. For the early detection of endometrial cancer 
it is crucial to screen high-risk patients: obese, endometrial hyperplasia in the case 
history, HRT and tamoxifen treatment. 
2. Endometrial thickness as measured by transvaginal sonography is considered to be 
a biomarker with respect to estrogen exposure, and its measurement is applicable 
for the examination of proliferative activity of the endometrium. Endometrial 
thickness showed good correlation with pathologic endometrial histologic 
findings. Below 4mm cut-off value of  endometrial thickness only one case of 
endometrial hyperplasia was diagnosed. No case of endometrial carcinoma was 
detected below 8 mm of endometrial thickness. Transvaginal ultrasound 
examination is of value to pick up high-risk patients for endometrial pathologies, 
even in patients without sign and symptoms. Further examination of suspect cases 
with histology (curettage) or with endometrial sampling by biopsy will help us to 
conclude to the final diagnosis. 
3. Three-dimensional ultrasound volumetry is helpful in the early detection of 
postmenopausal endometrial pathology, and allows more exact calculation 
compared to 2D-scan. Although expensive and time-consuming 3D-volumetry is 
not recommended for routine screening, but it is a definitely helpful adjunct to the 
differencial diagnosis of abnormal uterine bleeding. 
4. The results of our receptor studies strongly suggest, that non-genomic effect of 
estradiol is active even in the human postmenopausal endometrium. 
5. The activity of Akt/PKB and of estrogen receptors shows parallel changes with 
serum estrogen levels. 
6. Based on our findings phosphorylation of Akt and ER (activity) is increased in 
response to HRT (continuous combined estrogen+progesterone treatment) in spite 
of relatively low estradiol levels. Endometrial sampling via biopsy as part of 
routine gynecologic screening and further molecular biologic examination of non-
genomic effects of estrogen may be feasible to predict the prognosis of an early-
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